Clinical use of lenvatinib in patients with previous renal and/or hepatic impairment and radioiodine‐refractory differentiated thyroid cancer

Abstract Lenvatinib is one the most active drugs in radioiodine‐refractory differentiated thyroid cancer (RR‐DTC) such that it has become an important therapeutic tool in tumor control and survival. Renal and hepatic impairments are common comorbidities in cancer patients. Treating these patients is...

Ausführliche Beschreibung

Bibliografische Detailangaben

1. Verfasser:	Javier Martínez‐Trufero
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	Wiley 2022-10-01
Schriftenreihe:	Cancer Medicine
Schlagworte:	hepatotoxicity lenvatinib radioiodine refractory differentiated thyroid carcinoma renal impairment
Online-Zugang:	https://doi.org/10.1002/cam4.5130
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!